Marksans Pharma Limited announced that its second manufacturing facility in Verna, Goa, successfully completed a current Good Manufacturing Practice (cGMP) inspection conducted by the US Food and Drug Administration (US FDA) with zero Form 483 observations.
The inspection was carried out from November 3 to November 7, 2025, and concluded without any compliance issues, indicating that the facility met all US FDA regulatory standards. The Verna plant is one of the company’s key manufacturing units catering to the global pharmaceutical market.
Commenting on the development, Mr. Mark Saldanha, Managing Director of Marksans Pharma, said, “The successful outcome of the cGMP inspection by the US FDA is a testament to our ongoing commitment to product quality and regulatory compliance.”
Marksans Pharma, headquartered in Mumbai, is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations across major therapeutic areas such as cardiovascular, central nervous system, anti-diabetic, gastroenterological, and pain management. The company operates facilities in India, the US, and the UK, approved by regulators including US FDA, UK MHRA, and Australia’s TGA.
Disclaimer:
The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
